抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.015

摘要/Abstract

摘要： 头颈鳞癌(Head and neck squamous cell carcinoma,HNSCC)患者被诊断时多为晚期,传统方案治疗后复发率约为60%、转移率约为30%。而复发/转移性头颈鳞癌(Recurrent/metastasis HNSCC,R/M HNSCC)患者的治疗手段有限,长期生存率有待提高。免疫检查点抑制剂的出现有效的提高了这些患者的总生存期,为HNSCC患者带来了希望。本文总结了近年来程序性死亡蛋白1(PD-1)、程序性死亡蛋白1配体(PD-L1)和细胞毒性T淋巴细胞相关抗原4(CTLA-4)抑制剂及其组合疗法在头颈鳞癌中的研究进展,希望为临床医师提供新的治疗方案。

关键词: PD-1, PD-L1, CTLA-4, 免疫治疗, 头颈鳞癌

Abstract: Most patients with head and neck squamous cell carcinoma(HNSCC)are in advanced stage when they are diagnosed.The recurrence rate and metastasis rate of traditional regimen are about 60% and 30%,respectively.However,the treatment of recurrent and metastatic HNSCC(R/M HNSCC)is limited,and the long-term survival rate needs to be improved.The emergence of immune checkpoint inhibitors can effectively improve the overall survival of these patients,and bring hope for HNSCC patients.This paper summarizes the research progress of programmed death protein-1(PD-1),programmed death ligand-1(PD-L1)and cytotoxic T lymphocyte associated antigen 4(CTLA-4)inhibitors and their combination therapy in HNSCC in recent years,hoping to provide a new treatment for clinicians.

Key words: PD-1;PD-L1;CTLA-4;Immunotherapy;Head and neck squamous cell carcinoma

中图分类号:

R739.81

王明明, 陈晓品. 抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 179-183.

WANG Mingming, CHEN Xiaopin. Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma[J]. Journal of Practical Oncology, 2021, 35(2): 179-183.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.02.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I2/179

参考文献

1 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):359-386.
2 Vanoijen MG,Slootweg PJ.Oral field cancerization:carcinogen-induced independent events or micrometastatic deposits[J].Cancer Epidemiol Biomarkers Prev,2000,9(3):249-256.
3 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
4 Pan R,Zhu M,Yu C,et al.Cancer incidence and mortality:a cohort study in China,2008-2013[J].Int J Cancer,2017,141(7):1315-1323.
5 Nwizu T,Adelstein D.Pharmacotherapy of head and neck cancer[J].Expert Opin Pharmacother,2015,16(16):2409-2422.
6 Seiwert TY,Cohen EE.State-of-the-art management of locally advanced head and neck cancer[J].Br J Cancer,2005,92(8):1341-1348.
7 Pulte D,Brenner H.Changes in survival in head and neck cancers in the late 20th and early 21st century:a period analysis[J].Oncologist,2010,15(9):994-1001.
8 Marur S,Forastiere AA.Head and neck cancer:changing epidemiology,diagnosis,and treatment[J].Mayo Clin Proc,2008,83(4):489-501.
9 Napolitano M,Schipilliti FM,Trudu L,et al.Immunotherapy in head and neck cancer:The great challenge of patient selection[J].Crit Rev Oncol Hematol,2019,144:102829.
10 Pignon JP,le Maître A,Maillard E,et al.Meta-analysis of chemotherapy in head and neck cancer(MACH-NC):an update on 93 randomised trials and 17346 patients[J].Radiother Oncol,2009,92(1):4-14.
11 Bourhis J,Le Maître A,Baujat B,et al.Individual patients' data meta-analyses in head and neck cancer[J].Curr Opin Oncol,2007,19(3):188-194.
12 Posner MR,Hershock DM,Blajman CR,et al.Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer[J].N Engl J Med,2007,357(17):1705-1715.
13 Brockstein B,Haraf DJ,Rademaker AW,et al.Patterns of failure,prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy:a 9-year,337-patient,multi-institutional experience[J].Ann Oncol,2004,15(8):1179-1186.
14 Sunshine J,Taube JM.PD-1/PD-L1 inhibitors[J].Curr Opin Pharmacol,2015,23:32-38.
15 Krummel MF,Allison JP.CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation[J].J Exp Med,1995,182(2):459-465.
16 Ferris RL,Blumenschein GJ,Fayette J,et al.Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J].N Engl J Med,2016,375(19):1856-1867.
17 Ferris RL,Blumenschein G,Fayette J,et al.Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck:2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J].Oral Oncol,2018,81:45-51.
18 曾玉兰,刘洋洋,梁金燕,等.免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J].实用肿瘤学杂志,2017,31(4):353-358.
19 Ferris RL,Gillison ML,Harris J,et al.Safety evaluation of nivolumab(Nivo)concomitant with cetuximab-radiotherapy for intermediate(IR)and high-risk(HR)local-regionally advanced head and neck squamous cell carcinoma(HNSCC):RTOG 3504[J].J Clin Oncol,2018,36(15-suppl):6010.
20 Mcbride SM,Sherman EJ,Tsai CJ,et al.A phase II randomized trial of nivolumab with stereotactic body radiotherapy(SBRT)versus nivolumab alone in metastatic(M1)head and neck squamous cell carcinoma(HNSCC)[J].J Clin Oncol,2018,36(15 suppl):6009.
21 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicentre,phase 1b trial[J].Lancet,2016,17(7):956-965.
22 Chow LQM,Haddad R,Gupta S,et al.Antitumor activity of pembrolizumab in biomarker-Unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma:results from the phase Ib KEYNOTE-012 expansion cohort[J].J Clin Oncol,2016,34(32):3838-3845.
23 Cohen EEW,Soulières D,Le Tourneau C,et al.Pembrolizumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma(KEYNOTE-040):a randomised,open-label,phase 3 study[J].Lancet,2019,393(10167):156-167.
24 Burtness B,Harrington KJ,Greil R,et al.Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048):a randomised,open-label,phase 3 study[J].Lancet,2019,394(10212):1915-1928.
25 Powell SF,Gitau MM,Sumey CJ,et al.Safety of pembrolizumab with chemoradiation(CRT)in locally advanced squamous cell carcinoma of the head and neck(LA-SCCHN)[J].J Clin Oncol,2017,35(15 suppl):6011.
26 Sun XS,Sire C,Tao Y,et al.A phase II randomized trial of pembrolizumab versus cetuximab,concomitant with radiotherapy(RT)in locally advanced(LA)squamous cell carcinoma of the head and neck(SCCHN):first results of the GORTEC 2015-01 "PembroRad" trial[J].J Clin Oncol,2018,36(15 suppl):6018.
27 Wise-Draper TM,Old MO,Worden FP,et al.Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma[J].J Clin Oncol,2018,36(15 suppl):6017.
28 Wang F,Wei X,Feng JF,et al.Recombinant humanized anti-PD-1 monoclonal antibody(JS001)in patients with refractory/metastatic nasopharyngeal carcinoma:interim results of an open-label phase II clinical study[J].J Clin Oncol,2019,37(15 suppl):6017.
29 Fang W,Yang Y,Ma Y,et al.Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma:results from two single-arm,phase 1 trials[J].Lancet Oncol,2018,19(10):1338-1350.
30 Zandberg DP,Algazi AP,Jimeno A,et al.Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma:Results from a single-arm,phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy[J].Eur J Cancer,2019,107:142-152.
31 Siu LL,Even C,Mesía R,et al.Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/Negative recurrent or metastatic HNSCC[J].JAMA Oncol,2019,5(2):195.
32 Licitra LF,Haddad RI,Even C,et al.EAGLE:A phase 3,randomized,open-label study of durvalumab(D)with or without tremelimumab(T)in patients(pts)with recurrent or metastatic head and neck squamous cell carcinoma(R/M HNSCC)[J].J Clin Oncol,2019,37(15 suppl):6012.
33 Heery CR,O'Sullivan-Coyne G,Madan RA,et al.Avelumab for metastatic or locally advanced previously treated solid tumours(JAVELIN Solid Tumor):a phase 1a,multicohort,dose-escalation trial[J].Lancet Oncol,2017,18(5):587-598.
34 Elbers JBW,Al-Mamgani A,Tesseslaar MET,et al.Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma:results from a phase-I trial[J].Radiother Oncol,2020,142:79-84.
35 Colevas AD,Bahleda R,Braiteh F,et al.Safety and clinical activity of atezolizumab in head and neck cancer:results from a phase I trial[J].Ann Oncol,2018,29(11):2247-2253.

[1]	王萌萌, 连洁, 李恒震, 张艳桥. 胃肠胰神经内分泌肿瘤的免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 154-159.
[2]	李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.
[3]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[4]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[5]	张连齐, 李吉辰, 朴松林, 赛音乌力吉, 元冬梅, 沈禹辰. PD-L1与MTA1在口腔鳞癌中的表达与临床意义[J]. 实用肿瘤学杂志, 2020, 34(3): 220-224.
[6]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[7]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[8]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[9]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[10]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[11]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.
[12]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[13]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.
[14]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.
[15]	马悦,陶冀. MSI结直肠癌的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 376-380.